Literature DB >> 6338702

Lymphoblastic lymphoma with the phenotype of common acute lymphoblastic leukemia.

M J Borowitz, B P Croker, R S Metzgar.   

Abstract

Immunologic phenotyping of lymphoblastic lymphomas has shown that most of these are tumors of T-cell origin. In this report, we describe two patients with biopsy-proven lymphoblastic lymphoma whose tumors had no T-cell markers when tested by immunoperoxidase with a large panel of monoclonal antibodies. However, the tumor cells did express the common ALL antigen (CALLA), Ia antigen, and a 24,000 dalton ALL-associated antigen defined by monoclonal antibody DU-ALL-1. The tumor cells also lacked surface immunoglobulin. Although this phenotype is that seen in most cases of acute lymphoblastic leukemia, the patients were never leukemic at any time during their clinical course. Our results support the overall similarity between lymphoblastic lymphoma and acute lymphoblastic leukemia. Further, they suggest that it may be possible to identify prognostically significant immunologic subtypes of lymphoblastic lymphoma.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6338702     DOI: 10.1093/ajcp/79.3.387

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  4 in total

1.  B lymphoblastic lymphoma presenting as a tumor of the nasopharynx in an adult patient.

Authors:  Rodrigo Lopes da Silva; Teresa Fernandes; Alexandra Lopes; Susana Santos; Manuela Mafra; António Silva Rodrigues; Aida Botelho de Sousa
Journal:  Head Neck Pathol       Date:  2010-08-22

2.  In vivo antitumor activity demonstrated with squamous carcinoma reactive monoclonal antibody-Vinca immunoconjugates.

Authors:  D A Johnson; J L Zimmermann; B C Laguzza; J N Eble
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

3.  Correlation between immunophenotypic diversity and clinical features in B-cell lymphoblastic lymphoma.

Authors:  K Shibata; Y Shimamoto; H Yamada; M Miyahara; N Fukushima; H Yano
Journal:  Ann Hematol       Date:  1995-12       Impact factor: 3.673

Review 4.  [Lymphomas and lymphatic leukemias in the bone marrow].

Authors:  P Adam; L Quintanilla-Fend; F Fend
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.